Why Is Larimar Therapeutics Stock Plunging Despite Positive CTI-1601 Data?

  • Larimar Therapeutics Inc LRMR shares are trading lower despite announcing positive topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich's Ataxia (FA).
  • The data showed that repeated subcutaneous injections of CTI-1601 led to dose-dependent increases in FXN levels from baseline versus the placebo controls.
  • The repeated subcutaneous injections of CTI-1601 were generally well tolerated at doses up to 100mg administered daily for 13 days.
  • According to the company's 10-Q filing for Q1, the results from the non-human primate studies for the CTI-1601 program implied some safety concerns.
  • The company has reported mortality in a 90-day non-human primate study which is believed to be due to bacterial meningitis infection and had no connection with the drug.
  • In addition, mortalities have been observed in the ongoing 180 day-non-human primate study at the highest dose levels.  
  • The company says that it has informed the FDA of these findings and continues to dose non-human primates in the study and continue to collect and evaluate data.  
  • It says that additional non-clinical information may be required before initiating further clinical studies, based on all the information it has from the non-clinical program to date.
  • Price Action: LRMR shares dropped 33.3% at $8.75 during the market trading session on the last check Tuesday.

Posted In: BriefsFriedreich's AtaxiaBiotechNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.